Open Orphan #ORPH – Venn Life Sciences New Contract Win

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce Open Orphan’s Paris subsidiary Venn Life Sciences (“Venn”) has secured an important new contract to support a major European pharmaceutical company. The […]

Open Orphan #ORPH – New Contract Win with Carna Bioscience

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a new contract with Carna Bioscience ( www.carnabio.com ) for a First In Human Clinical pharmacology trial. The contract […]

Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, […]

Open Orphan #ORPH – Option to Acquire CHIMagents Limited

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce it has signed an option to acquire (the “Option”) CHIMagents Limited (“CHIMagents”) for a nominal sum. CHIMagents was recently established to assist […]

Open Orphan #ORPH – Upcoming Investor Events

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is delighted to be attending and presenting at a series of investor events from the 9th to 11th July 2020. Cathal Friel, Open Orphan’s Chief Executive Officer, will […]

Open Orphan #ORPH – Full Year Results

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is pleased to announce its full year results for the year ended 31 December 2019.   Financial Highlights Open Orphan plc (As reported) hVIVO plc (As reported) Open […]

Open Orphan #ORPH – Positive Phase 1 study results published in The Lancet

Monday 15th June, 2020 Positive results from the Phase I study of the AGS-v vaccine developed by an Open Orphan joint venture, Imutex Limited, have been published in the peer reviewed journal The Lancet AGS-v is a first-in-class mosquito saliva, standalone, vaccine candidate designed to protect against mosquito-borne diseases carried in the saliva such as Zika, Malaria, […]

Experts seek approval for COVID-19 trials – China Daily

By ANGUS McNEICE in London Medical community divided on issue of exposing humans to deadly virus A laboratory in the United Kingdom is hoping to become the first in the world to intentionally infect volunteers with novel coronavirus in order to test the efficacy of COVID-19 vaccines. Half of the participants in these so-called human […]